As of Nov 21, 2024, the Roivant Sciences stock's PE ratio is 1.99. This results from the current EPS of $5.95 and stock price of $11.82. The P/E ratio has an increase of 3.9% from the past four quarters average of 1.9.
Year | PE ratio | Change |
---|---|---|
2024 | 1.9 | N/A |
2023 | N/A | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
ROIV's PE ratio is lower than its peer stock ORMP.
Stock name | PE ratio | Market cap |
---|---|---|
ROIV Roivant Sciences Ltd | 1.99 | $8.6B |
ORMP Oramed Pharmaceuticals Inc | 21 | $93.12M |
OLMA Olema Pharmaceuticals Inc | N/A | $450.93M |
OMER Omeros Corp | N/A | $447.95M |
OMGA Omega Therapeutics Inc | N/A | $42.96M |
ONCT Oncternal Therapeutics Inc | N/A | $3.43M |
ONVO Organovo Holdings Inc | N/A | $5.38M |
ORIC Oric Pharmaceuticals Inc | N/A | $643.57M |
ROIV's price to earnings ratio is 1.99 as of Nov 21, 2024.
ROIV's PE ratio is low because its earnings per share (EPS) is high relative to its stock price.
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (Nov 21, 2024), Roivant Sciences's stock price is $11.82. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $5.95. Therefore, Roivant Sciences's P/E ratio for today is 1.99. PE RATIO(1.99) = STOCK PRICE($11.82) / TTM EPS($5.95)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.